logo

ACRV

Acrivon Therapeutics·NASDAQ
--
--(--)
--
--(--)
5.75 / 10
Netural

Fundamental measurement shows fair quality with a score of 5.8/10. Key strengths include favorable PB-ROE and Asset-MV factors, while caution is advised for Net profit / Total profit (%) and Revenue-MV due to mixed historical performances. Overall, the company presents balanced but not outstanding fundamentals.

Fundamental(5.75)SentimentTechnical

Analysis Checks(7/10)

Revenue-MV
Value-0.26
Score1/3
Weight9.19%
1M Return5.20%
Inventory turnover ratio
Value47.85
Score3/3
Weight8.07%
1M Return5.26%
Gross profit margin (%)
Value36.70
Score1/3
Weight-0.71%
1M Return-0.54%
Profit-MV
Value0.46
Score2/3
Weight13.76%
1M Return7.79%
PB-ROE
Value-0.66
Score3/3
Weight21.61%
1M Return11.47%
Current assets turnover ratio
Value1.78
Score2/3
Weight1.61%
1M Return1.15%
Fixed assets turnover ratio
Value7979.42
Score3/3
Weight1.17%
1M Return0.86%
Asset-MV
Value-0.50
Score3/3
Weight31.93%
1M Return14.99%
Cash-MV
Value-0.07
Score2/3
Weight13.78%
1M Return7.73%
Net profit / Total profit (%)
Value100.00
Score0/3
Weight-0.41%
1M Return-0.30%
Is ACRV undervalued or overvalued?
  • ACRV scores 5.75/10 on fundamentals and holds a Fair valuation at present. Backed by its -38.59% ROE, 0.00% net margin, -0.61 P/E ratio, 0.41 P/B ratio, and 20.30% earnings growth, these metrics solidify its Netural investment rating.